Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
98
-
Total 13F shares, excl. options
-
31M
-
Shares change
-
+1.2M
-
Total reported value, excl. options
-
$101M
-
Value change
-
-$1.24M
-
Put/Call ratio
-
0.25
-
Number of buys
-
56
-
Number of sells
-
-45
-
Price
-
$3.26
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q2 2024
126 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q2 2024.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 98 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31M shares
of 49.6M outstanding shares and own 62.39% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (3.6M shares), BlackRock Inc. (3.57M shares), MILLENNIUM MANAGEMENT LLC (3.16M shares), Frazier Life Sciences Management, L.P. (3.06M shares), ACADIAN ASSET MANAGEMENT LLC (1.95M shares), RENAISSANCE TECHNOLOGIES LLC (1.75M shares), GREAT POINT PARTNERS LLC (1.49M shares), Eversept Partners, LP (1.33M shares), Athyrium Capital Management, LP (1.26M shares), and GEODE CAPITAL MANAGEMENT, LLC (950K shares).
This table shows the top 98 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.